Long-term effect of empagliflozin and dapagliflozin in patients with heart failure undergoing coronary artery surgery/endovascular intervention: Is there a difference between these two SGLT2i on hospitalization, MACE, and mortality?
Abstract
Long-term effect of empagliflozin and dapagliflozin in patients with heart failure undergoing coronary artery surgery/endovascular intervention: Is there a difference between these two SGLT2i on hospitalization, MACE, and mortality?
Objective: This study aims to compare the long-term effects of these two Sodium-Glucose Co-Transporter 2 inhibitors (SGLT2i) on hospitalization, major adverse cardiovascular events (MACE), and mortality in heart failure patients undergoing coronary artery bypass graft surgery (CABG)/percutaneous coronary intervention (PCI) on empagliflozin and dapagliflozin.
Methods: 567 patients with heart failure undergoing CABG/PCI between 2014 and 2022 were studied, and 470 patients on empagliflozin and dapagliflozin were analyzed. The two groups of patients with preserved ejection fraction (HFpEF, n= 293) and patients with low/slightly reduced ejection fraction (HFdEF, n= 177) were analyzed in two subgroups: empagliflozin and dapagliflozin users. In addition to hospitalization, MACE and mortality, age, gender, disease history, and laboratory parameters were compared. Patients with (n=123) and without (n=347) cardiac MACE were also compared.
Results: No significant difference was found between the groups in terms of age, HbA1c, creatinine levels, and other cardiovascular risk factors. Similar results were obtained in terms of overall mortality, cardiac mortality, MACE, cardiac MACE, and hospitalization. In the HFpEF group comparing dapagliflozin with…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.